Abbott Laboratories (ABT) beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices. The company also maintained its full-year profit forecast of $5.05 to $5.25 per share in the face of an escalating global trade war.
Leave A Comment